Vector BioMed collaborates with partners to help them reach clinical studies and prepare to commercialize their lentiviral vector–based medicines through a best-in-class lentiviral vector platform. Piloted by a team comprising members who led the first-ever lentiviral vector clinical trial in humans, Vector BioMed has a proven track record for preclinical and GMP lentiviral vector production and a platform designed to optimize titer and transgene function. The Gaithersburg, Maryland–based company specializes in streamlined processes that cut costs and expand access to both generic and novel cell and gene therapies.